Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 9

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 9
---
 would be executive directors designated by NewGenIvf and three (3) of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately after the consummation of the Business Combination. On April 3, 2024, the Business Combination was consummated with the Company as the surviving entity. NewGenIvf’s Business With a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i) in vitro fertilization (“IVF”) treatment service, comprising traditional IVF and egg donation; and (ii) surrogacy and ancillary caring services. Currently, we have four clinics: two clinics in Thailand (one of which, whilst licensed, is yet to commence operations), one clinic in Cambodia, and one clinic in Kyrgyzstan.

<div align='center'>2</div>

For the years ended
December 31, 2024 and 2023, NewGenIvf’s revenue was US$5,433,375 and US$5,136,153, and its net income/(loss) was US$(474,101) and
US$108,418, respectively.

Competitive Strengths

NewGenIvf believes that the
following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific, and have
differentiated it from its competitors:

Broad-range Assisted Reproductive Service (“ARS”) Provider Offering Comprehensive Fertility Treatment Services

With almost a decade of experience
in the fertility market, NewGenIvf has built a reputation in the IVF industry in Asia-Pacific. NewGenIvf has reinforced its long-standing
position through expanding its service offerings and locations to address the evolving clients’ needs or requests.

NewGenIvf’s comprehensive
fertility treatment offerings in Thailand, Cambodia, and Kyrgyzstan, primarily including IVF, egg donation (in Cambodia) and surrogacy
services (in Kyrgyzstan), make it convenient for clients in Asia-Pacific market to have access to various fertility services but with
a relatively low cost, as compared with the US market. Meanwhile, the average cost